Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Buy" by Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been given a consensus recommendation of "Buy" by the ten ratings firms that are currently covering the stock, Marketbeat Ratings reports. Ten research analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the stock in the last year is $36.60.

A number of research firms have issued reports on VRDN. HC Wainwright reiterated a "buy" rating and issued a $37.00 target price on shares of Viridian Therapeutics in a research report on Thursday, February 29th. Needham & Company LLC reiterated a "buy" rating and issued a $30.00 target price on shares of Viridian Therapeutics in a research report on Wednesday, March 20th. Oppenheimer increased their price target on shares of Viridian Therapeutics from $35.00 to $36.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 19th. B. Riley dropped their price target on shares of Viridian Therapeutics from $29.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, March 21st. Finally, Royal Bank of Canada restated an "outperform" rating and set a $35.00 price target on shares of Viridian Therapeutics in a research note on Thursday, December 14th.

Viridian Therapeutics Stock Performance

VRDN traded up $0.06 during trading on Thursday, reaching $16.32. The company's stock had a trading volume of 1,008,402 shares, compared to its average volume of 970,769. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.26 and a current ratio of 18.26. Viridian Therapeutics has a 52-week low of $10.93 and a 52-week high of $30.30. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -3.11 and a beta of 1.07. The company's fifty day moving average price is $18.48 and its 200-day moving average price is $17.51.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its earnings results on Tuesday, February 27th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.37). Viridian Therapeutics had a negative return on equity of 121.80% and a negative net margin of 75,711.48%. The company had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.15 million. During the same quarter in the previous year, the company earned ($1.13) EPS. The firm's quarterly revenue was down 31.4% compared to the same quarter last year. On average, equities analysts forecast that Viridian Therapeutics will post -4.39 earnings per share for the current fiscal year.

Insider Buying and Selling at Viridian Therapeutics

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc acquired 476,190 shares of Viridian Therapeutics stock in a transaction on Monday, January 22nd. The shares were purchased at an average cost of $21.00 per share, with a total value of $9,999,990.00. Following the completion of the purchase, the director now owns 1,839,954 shares in the company, valued at $38,639,034. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.43% of the company's stock.

Hedge Funds Weigh In On Viridian Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in VRDN. Metropolitan Life Insurance Co NY raised its holdings in shares of Viridian Therapeutics by 47.0% during the fourth quarter. Metropolitan Life Insurance Co NY now owns 2,340 shares of the company's stock worth $68,000 after acquiring an additional 748 shares during the period. Royal Bank of Canada increased its stake in Viridian Therapeutics by 48.8% in the 2nd quarter. Royal Bank of Canada now owns 3,199 shares of the company's stock valued at $76,000 after buying an additional 1,049 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Viridian Therapeutics by 1,874.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 3,218 shares of the company's stock valued at $82,000 after buying an additional 3,055 shares during the last quarter. Silverarc Capital Management LLC acquired a new position in shares of Viridian Therapeutics during the 4th quarter worth about $88,000. Finally, Legal & General Group Plc acquired a new position in shares of Viridian Therapeutics during the 2nd quarter worth about $94,000.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.